


Patent Docket P1974R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|--|--|
| In re Application of Daryl T. Baldwin et al. Serial No.: 10/658482 Filed: 09/09/2003 For: Novel Composition and Methods for the Treatment of Immune Related Diseases | Group Art Unit: 1645 Examiner: Not yet assigned Confirmation No: 3368 Customer No: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 11, 2004  Jennifer Fisk |
|--|--|

REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the corrections as indicated in red on the attached copy and as follows:

In the "Applicant(s)" section, please amend to read as follows;;
please replace "Palo Alto, CA" with --**Menlo Park, CA**-- after "Sarah C. Bodary";
please replace "Andrew C. Chen" with -- Andrew C. **Chan**--
please replace "Hillsborough, CA" with --**Cupertino, CA**-- after "William I. Wood".

Respectfully submitted,
GENENTECH INC.

Date: February 11, 2004

By: 
David A. Carpenter
Reg. No. 45,945
Telephone No. (650) 225-3733

DPA/CA/CA



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

| APPL NO. | FILING OR 371 (c) DATE | ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|-----------------|----------|----------|----------|
| 10/658,482 | 09/09/2003 | 1645 | 2022 | P1974R1 | 4 | 30 | 13 |

09157
 GENENTECH, INC.
 1 DNA WAY
 SOUTH SAN FRANCISCO, CA 94080



CONFIRMATION NO. 3368

FILING RECEIPT



OC000000011382453

Date Mailed: 12/01/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Daryl T. Baldwin, Berkeley, CA;
 Sarah C. Bodary, Palo Alto, CA; → Menlo Park
 Andrew C. Chen, Menlo Park, CA; → Chan
 Hilary Clark, San Francisco, CA;
 Janet K. Jackman, Half Moon Bay, CA;
 William I. Wood, Hillsborough, CA;
 C Cupertino

Assignment For Published Patent Application

Genentech, Inc., South San Francisco, CA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/410,062 09/11/2002

Foreign Applications

If Required, Foreign Filing License Granted: 11/29/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Novel composition and methods for the treatment of immune related diseases

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).